Amgen highlighted its increasingly global reach on the second quarter earnings call with Bob Bradway, chairman and CEO, in particular citing a recent deal with Daiichi Sankyo in Japan as key for biosimilar sales.
“With an expected 80 new launches across countries and products this year, and the recent re-acquisition of rights to many of our existing products outside the United States, we’re meaningfully expanding our global footprint,” Bradway told analysts on the July 27 earnings call.
“To that end, we recently announced that we had partnered with Daiichi Sankyo in an effort to bring Amgen biosimilars to the Japanese market.”
That deal will see Daiichi Sankyo market and sell 9 products, including approved and late-stage development biosimilars of adalimumab, bevacizumab (Avastin) and trastuzumab (Herceptin), though no mention was made at the time of the deal or on the call about rituximab (Rituxan), cetuximab (Erbitux) and infliximab (Remicade) that are part of Amgen’s biosimilar efforts.
Amgen has extensive dealings with Japanese firms and has relied on a mixture of research and sales and marketing help, as well as its own efforts. In June, for example, Osaka-based Takeda Pharmaceutical returned Japan rights for Amgen oncology candidates fulranumab (AMG-403) and trebananib (AMG-386).
But the California biotech does not break out the market by sales, with Tony Hooper, head of Global Commercial Operations, instead giving an overall figure outside the U.S. as international sales that rose 3% in the second quarter, “or 5% year over year, excluding the impact of foreign exchange. Europe was a strong contributor, with 11% unit growth.”
By EJ Lane
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
